The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years of age
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.13236 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Desmond Curran und 17 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Wavre, Belgium. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human, Respiratory Tract Infections. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline.
Abstract (Originalsprache)
Background
Respiratory syncytial virus (RSV) is a contagious pathogen causing acute respiratory infections (ARIs). Symptoms range from mild upper respiratory tract infections to potentially life‐threatening lower respiratory tract disease (LRTD). In adults ≥60 years old, vaccine efficacy of a candidate vaccine for older adults (RSVPreF3 OA) was 71.7% against RSV‐ARI and 82.6% against RSV‐LRTD (AReSVi‐006/NCT04886596). We present the patient‐reported outcomes (PROs) from the same trial at the end of the first RSV season in the northern hemisphere (April 2022).
Methods
In this phase 3 trial, adults aged ≥60 years were randomized (1:1) to receive one dose of RSVPreF3 OA vaccine or placebo. PROs were assessed using InFLUenza Patient‐Reported Outcome (FLU‐PRO), Short Form‐12 (SF‐12), and EuroQol‐5 Dimension (EQ‐5D) questionnaires. Peak FLU‐PRO Chest/Respiratory scores during the first 7 days from ARI episode onset were compared using a Wilcoxon test. Least squares mean (LSMean) of SF‐12 physical functioning (PF) and EQ‐5D health utility scores were estimated using mixed effects models.
Results
In the RSVPreF3 OA group ( N = 12,466), 27 first RSV‐ARI episodes were observed versus 95 in the Placebo group ( N = 12,494). Median peak FLU‐PRO Chest/Respiratory scores were lower in RSVPreF3 OA (1.07) versus Placebo group (1.86); p = 0.0258. LSMean group differences for the PF and EQ‐5D health utility score were 7.00 (95% confidence interval [CI]: −9.86, 23.85; p = 0.4125) and 0.0786 (95% CI: −0.0340, 0.1913; p = 0.1695).
Conclusions
The RSVPreF3 OA vaccine, in addition to preventing infection, attenuated the severity of RSV‐associated symptoms in breakthrough infections, with trends of reduced impact on PF and health utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK, Wavre, Belgium.
- Freelance c/o GSK, Wavre, Belgium.
- CAP Centelles, Barcelona, Spain.
- Vaccine Research, FISABIO-Public Health, Valencia, Spain.
- Finnish Vaccine Research, Tampere, Finland.
- Department of Clinical Medicine, George Washington University School of Medicine & Health Sciences, Washington, District of Columbia, USA.
ORCID-Profile: Desmond Curran
Förderung
- GlaxoSmithKline
Zitieren
APA
Curran, D., Matthews, S., Cabrera, E. S., Pérez, S. N., Breva, L. P., Rämet, M., Helman, L., Park, D. W., Schwarz, T. F., Melendez, I. M. G., Schaefer, A., Roy, N., Stephan, B., Molnar, D., Kostanyan, L., Powers, J. H., Hulstrøm, V., & Members of the AReSVi‐006 Study Group (2024). The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years of age. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13236
Vancouver
Curran D, Matthews S, Cabrera ES, Pérez SN, Breva LP, Rämet M, et al. The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years of age. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13236
BibTeX
@article{Curran2024,
author = {Curran, Desmond and Matthews, Sean and Cabrera, Eliazar Sabater and Pérez, Silvia Narejos and Breva, Lina Pérez and Rämet, Mika and Helman, Laura and Park, Dae Won and Schwarz, Tino F and Melendez, Isabel Maria Galan and Schaefer, Axel and Roy, Nathalie and Stephan, Brigitte and Molnar, Daniel and Kostanyan, Lusine and Powers, John H and Hulstrøm, Veronica and Members of the AReSVi‐006 Study Group, Members of the AReSVi‐006 Study Group},
title = {The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years of age},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.13236}
}
EUVIMED